V. Fabien

W. Aberer, M. Maurer, H. Longhurst, 2016, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Long‐term safety of icatibant treatment of patients with angioedema in real‐world clinical practice

M. Triggiani, W. Aberer, B. Goichot, 2017, Allergy.

University of Southern Denmark Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice Zanichelli,

W. Aberer, H. Longhurst, L. Bouillet, 2017 .

Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment

W. Aberer, A. Kaplan, M. Maurer, 2013, PloS one.

Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant

A. Gompel, D. Launay, G. Kanny, 2017, Immunity, inflammation and disease.

Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals

W. Aberer, M. Maurer, H. Longhurst, 2015, International Archives of Allergy and Immunology.

Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting.

W. Lumry, M. Maurer, H. Longhurst, 2014, Allergy and asthma proceedings.

The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks

W. Aberer, M. Maurer, H. Longhurst, 2015, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

Analysis of characteristics associated with reinjection of icatibant: Results from the icatibant outcome survey.

W. Aberer, M. Maurer, H. Longhurst, 2015, Allergy and asthma proceedings.

Triggers and Prodromal Symptoms of Angioedema Attacks in Patients With Hereditary Angioedema.

W. Aberer, M. Maurer, H. Longhurst, 2016, Journal of investigational allergology & clinical immunology.

Rationale and design of the AFFIRM‐AHF trial: a randomised, double‐blind, placebo‐controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron‐deficient patients admitted for acute heart failure

P. Ponikowski, G. Filippatos, A. Keren, 2019, European journal of heart failure.

Responder analysis for improvement in 6‐min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency

P. Ponikowski, I. Piña, G. Filippatos, 2022, European journal of heart failure.

Correction: Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment

W. Aberer, A. Kaplan, M. Maurer, 2013 .

Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis

G. Filippatos, M. Metra, J. Butler, 2023, Circulation.

Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial

G. Filippatos, M. Metra, F. Ruschitzka, 2023, Cardiovascular Diabetology.